Smartwatches could revolutionize monitoring of rare nerve disease
NCT ID NCT07273903
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether smartwatches can help monitor chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disease that causes weakness and numbness. 35 adults with CIDP who use subcutaneous immunoglobulin therapy at home will wear a smartwatch for 12 months. Researchers will compare step counts and activity levels with standard clinical tests to see if the watch can detect changes in disease severity or treatment response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- subcutaneous immunoglobulin (fSCIG)
- What this could lead to
- If successful, this could show that smartwatches help doctors monitor CIDP more closely and adjust treatment earlier, leading to better long-term care.
- What could go wrong
- This is a small, early observational study (35 people) that does not test a new treatment. The smartwatch data may not reliably reflect disease changes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIDP - CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital Düsseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
-
University Hospital Münster
RECRUITINGMünster, North Rhine-Westphalia, 48149, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.